Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke

Endovascular thrombectomy and intravenous thrombolysis have become key therapeutic approaches for acute ischemic stroke. However, due to time window limitations, many patients are unable to receive reperfusion therapy, and the majority only receive supportive treatment. Ischemic stroke-related complications, including edema and infection, gradually subside after 7 days post-stroke, with the patient's condition generally stabilizing. Endogenous repair mechanisms will play a critical role in the coming months. This study aims to predict prognostic biomarkers for ischemic stroke patients who have not undergone reperfusion therapy, using blood proteomics data. All samples in our study are derived from this experiment. Our goal is to elucidate the molecular mechanisms underlying post-reperfusion prognosis and to provide insights for optimizing stroke treatment strategies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Xuanwu Hospital, Beijing, Beijing Municipality, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18.
Clinical signs consistent with acute ischemic stroke (TOAST classification: large artery atherosclerosis)
7 to 30 days from symptom onset.

Exclusion criteria

Severe infection or multiple organ failure.
Untreated moderate or severe coronary artery stenosis, or a history of coronary artery bypass surgery.
Ongoing hemodialysis or peritoneal dialysis, or severe renal insufficiency characterized by a glomerular filtration rate (GFR) of less than 30 ml/min or serum creatinine levels exceeding 220 mmol/L (2.5 mg/dl).
Known intracranial aneurysm or cerebral arteriovenous malformation.
Malignant brain tumor or central nervous system (CNS) infection.
Pre-existing neurological or psychiatric conditions that could confound the neurological or functional assessments.
Baseline platelet count <50 × 109/L.
Pregnancy or lactation at the time of admission.

Treatment and study plan

The blood Proteome Profiling

Diagnostic Test

Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.

Primary outcomes

Primary Outcome Measures:

Time frame: 3 months

Modified Rankin Scale score (mRS) at 90 days The Modified Rankin Scale (mRS) at 90 days was used to assess functional outcomes. The mRS is a widely utilized scale to measure the degree of disability or dependence in daily activities among stroke patients.

Minimum value: 0 (indicating no symptoms or disability) Maximum value: 6 (indicating death) Interpretation: Higher scores represent worse outcomes, reflecting greater levels of disability or mortality.

Sponsors and collaborators

Lead sponsor

Capital Medical University

Other

Registry information

Official study title

The Blood Proteome Profiling Identifies Biomarkers Associated with Prognosis in Ischemic Stroke Due to Large Artery Atherosclerosis

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Dec 11, 2024
Registry last updated: Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed